Asundexian inferior to apixaban for stroke prevention in atrial fibrillation: Study

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session Sept. 1 at ESC Congress 2024.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup